AR and prostate carcinoma: The PARP7 inhibitor RBN2397 is currently tested in phase-1 clinical trials, both in breast and lung cancer cells, enhancing the IFN-I signalling pathways negatively regulated by PARP7, and in prostate cancer cells, where PARP7 regulates the stability of AR, leading to an inhibition of prostate cancer cells growth in culture (Ref.